2026-09-14T13:25:41Zhttps://gredos.usal.es/oai/request

oai:gredos.usal.es:10366/1543092026-06-19T14:43:00Zcom_10366_4019com_10366_3947com_10366_3946com_10366_3823col_10366_4020

Mateos Manteca, María Victoria Gutiérrez Gutiérrez, Norma Carmen Martín-Ramos, María-Luisa Lourenço Paiva, Bruno Montalbán, María-Angeles Oriol, Albert Martínez-López, Joaquín Teruel, Ana-Isabel Bengoechea, Enrique Martín, Alejandro Díaz-Mediavilla, Joaquín De Arriba, Felipe Palomera, Luis Hernández, José-Mariano Sureda, Anna Bargay, Joan Peñalver, Francisco-Javier Ribera Santasusana, Josép María Martín-Mateos, María-Luisa Fernández, Manuela García Sanz, Ramón Vidriales Vicente, María Belén Bladé, Joan Lahuerta, Juan-José San Miguel Izquierdo, Jesús Fernando 2024-01-16T13:07:13Z 2024-01-16T13:07:13Z 2011-10-27 Mateos, M. V., Gutiérrez, N. C., Martín-Ramos, M. L., Paiva, B., Montalbán, M. A., Oriol, A., ... & San Miguel, J. F. (2011). Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. Blood, The Journal of the American Society of Hematology, 118(17), 4547-4553. https://doi.org/10.1182/blood-2011-04-345801 0006-4971 http://hdl.handle.net/10366/154309 10.1182/blood-2011-04-345801 21900193 1528-0020 [EN]Cytogenetic abnormalities (CAs) such as t(4;14), t(14;16) or del(17p), and nonhyperdiploidy are associated with poor prognosis in multiple myeloma. We evaluated the influence of CAs by FISH and DNA ploidy by flow cytometry on response and survival in 232 elderly, newly diagnosed multiple myeloma patients receiving an induction with weekly bortezomib followed by maintenance therapy with bortezomib-based combinations. Response was similar in the high-risk and standard-risk CA groups, both after induction (21% vs 27% complete responses [CRs]) and maintenance (39% vs 45% CR). However, high-risk patients showed shorter progression-free survival (PFS) than standard-risk patients, both from the first (24 vs 33 months; P = .04) and second randomization (17 vs 27 months; P = .01). This also translated into shorter overall survival (OS) for high-risk patients (3-year OS: 55% vs 77%; P = .001). This adverse prognosis applied to either t(4;14) or del(17p). Concerning DNA ploidy, hyperdiploid patients showed longer OS than nonhyperdiploid patients (77% vs 63% at 3 years; P = .04), and this was more evident in patients treated with bortezomib, thalidomide, and prednisone (77% vs 53% at 3 years; P = .02). The present schema does not overcome the negative prognosis of high-risk CAs and nonhyperdiploidy. This trial was registered with www.ClinicalTrials.gov as NCT00443235. eng http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Attribution-NonCommercial-NoDerivatives 4.0 Internacional Mieloma múltiple Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance info:eu-repo/semantics/article